A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00294710
- Lead Sponsor
- Novartis
- Brief Summary
This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 976
Inclusion Criteria
- Patients with essential hypertension
Exclusion Criteria
- Severe hypertension
- History or evidence of a secondary form of hypertension
- History of myocardial infarction.
- Other protocol-defined inclusion exclusion criteria also apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in diastolic blood pressure after 52 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline in systolic and diastolic blood pressure after 52 weeks Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 52 weeks Achieve blood pressure control target of < 140/90 mmHg after 12 weeks
Trial Locations
- Locations (1)
Novartis
🇺🇸East Hanover, New Jersey, United States